Disclosures: Edward Gane: Nothing to Disclose, Tawesak Tanwandee: Roche: Grant/Research Support, MSD: Grant/Research Support, Altimune: Grant/Research Support, Gilead: Grant/Research Support, Vir Biotech: Grant/Research Support, Bitna Yi: Gilead Sciences, Inc.: Employee, Teri Chew: Gilead Sciences, Inc: Employee, Irina Botros: Nothing to Disclose, Danielle Shing: Nothing to Disclose, Heba Abdullah: Nothing to Disclose, Leonard Sowah: GILEAD Sciences, Inc: Employee, Frida Abramov: Gilead Sciences, Inc: Employee, Gilead Sciences, Inc: Stock - publicly traded company, Ben Da: Nothing to Disclose, Audrey Lau: Nothing to Disclose, Anu Osinusi: Nothing to Disclose, Tak Yin Owen Tsang: Nothing to Disclose, Anchalee Avihingsanon: Nothing to Disclose 368 DETECTION AND MONITORING OF INFANT DRUG EXPOSURE: A STUDY ON TFV CONCENTRATION IN TDF AND TAF Chengjing Tao Background: A few studies have observed the Tenofovir (TFV) concentration of Tenofovir Disoproxil Fumara (TDF) and Tenofovir Alafenamide Fumarate (TAF) in the blood, milk, and amniotic fluid of pregnant women, but few have investigated the concentration of TFV in infant blood and urine, which could aid in detecting and monitoring infant drug exposure
Notably, ARCs can be classified into distinct subtypes based on the location of opacification, including cortical cataracts, nuclear cataracts (NCs), and posterior and anterior subcapsular cataracts (ASCs), while the remainder is classified as mixed cataracts, and differential expression of miRNAs has been observed among these subtypes (72)
What are the different types of IV nutrition therapy
3g), reflecting patient-specific metabolic phenotypes and underscoring the potential of this platform for personalized drug metabolism studies
